Dinesh Dua, Director of Nectar Lifesciences Dinesh Dua said the company stands to gain from pharmacies destocking due to demonetisation. He expects a good Q4 show as chemists will restock supplies.

Will maintain current EBITDA levels: Nectar Lifesciences

In an interview with CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences spoke about the results and his outlook for the company.

Expect to grow about 10% next year: Nectar Lifesciences

In an interview with CNBC-TV18, Dinesh Dua, CEO, Nectar Lifesciences, shared his reading of the company's third quarter earnings and gave his outlook on the business going forward.

Awaiting US FDA approval for Baddi facility in FY16: Nectar

Dinesh Dua, CEO of Nectar Lifesciences said that the company is hopeful of receiving US FDA approval for its formulation facility in Baddi in current year.

Will make $10-20 mn annually on Brazil drug nod: Nectar

Dinesh Dua, chief executive officer, Nectar Life Sciences, expects the company‘s margin to be close to 20 percent.

Expect double-digit growth in FY15: Nectar Life

In an interview to CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences details the Q1 performance of the company and what he expects in the future.

See 2% margin growth in FY14: Nectar Lifesciences

In an upbeat mood post the numbers, Aryan Goyal of Nectar Lifesciences is confident that the company would see robust numbers going ahead.

API facility to boost revenue by 5-10%: Nectar Lifesciences

Nectar Lifesciences has received European approval for its Cephalosporin APIs manufacturing facility at Derabassi in Punjab. Dinesh Dua, chief executive director at Nectar Lifesciences, in an interview to CNBC-TV18, said the API manufacturing facility is likely to boost the company’s revenues by 5-10%.

Regulated markets to fetch Rs 250-300cr in 2 years: Nectar

Dinesh Dua, CEO, Nectar Lifesciences in an interview with CNBC-TV18 spoke about the latest happenings in the company and the road ahead.

USFDA nod will open up lucrative market for us: Nectar Lifesciences

In an interview with CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences said, "It’s going to happen at April. As soon as the approval is through we will be able to supply our API to lots of customers."

Nectar Lifesciences targets Rs 1300cr revenues in FY12

In an interview with CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences said,"We are looking at about close to Rs 1,300 plus crore topline for the next year."

Nectar Lifesciences eyes Rs 1300cr topline in FY12

In an interview with CNBC-TV18’s Latha Venkatesh and Gautam Broker, Dinesh Dua, CEO of Nectar Lifesciences spoke about the results and the road ahead.